BELGRADE, Mont., May 26, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the
development of regenerative medicine products and medical devices, today announced that its board of directors has rescheduled the
Company's annual meeting of stockholders, originally scheduled for June 21, 2017, to a later date, as the Company continues to
evaluate its strategic alternatives. The Company will announce a new annual meeting date and record date when they are determined
by the board of directors, and will subsequently file and mail proxy materials as required.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) develops, manufactures and markets class-leading regenerative
medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of
orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for
the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing
following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies,
Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further
information, please visit
www.xtantmedical.com.
Important Cautions Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking
statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that
include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects,"
"forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or
similar expressions or the negative thereof.
Statements of historical fact also may be deemed to be forward-looking statements. We caution that these
statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of
important factors, including, among others: the ability to comply with covenants in the Company’s senior credit facility and to
make deferred interest payments; the ability to maintain sufficient liquidity to fund operations; the ability to remain listed on
the NYSE MKT; the ability to obtain financing on reasonable terms; the ability to increase revenue; the ability to continue as a
going concern; the ability to maintain sufficient liquidity to fund operations; the ability to achieve expected results; the
ability to remain competitive; government regulations; the ability to innovate and develop new products; the ability to obtain
donor cadavers for products; the ability to engage and retain qualified technical personnel and members of the Company’s management
team; the availability of Company facilities; government and third-party coverage and reimbursement for Company products; the
ability to obtain regulatory approvals; the ability to successfully integrate recent and future business combinations or
acquisitions; the ability to use net operating loss carry-forwards to offset future taxable income; the ability to deduct all or a
portion of the interest payments on the notes for U.S. federal income tax purposes; the ability to service Company debt; product
liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical
studies; the ability to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of
intellectual property; the ability to remain accredited with the American Association of Tissue Banks; influence by Company
management; the ability to pay dividends; and the ability to issue preferred stock; and other factors.
Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form
10-Q under the heading "Risk Factors." You should carefully consider the trends, risks and uncertainties described in this
document, the Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to
our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or
operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose
all or part of your investment. The Company undertakes no obligation to release publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as
required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their
entirety by this cautionary statement.
Investor Contact CG CAPITAL Rich Cockrell 877.889.1972 investorrelations@cg.capital Company Contact Xtant Medical Molly Mason mmason@xtantmedical.com